A-Level Capital

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Yet Analytics, Inc. is a data analytics company based in Baltimore, Maryland, founded in 2014. It provides a platform that enables large businesses to collect and analyze data from various sources, including web and mobile applications, wearables, Internet of Things devices, and virtual and augmented reality systems. The company's modular suite of software products supports the xAPI learning technology ecosystem, offering solutions for data input, storage, and output. By facilitating the integration of learning experiences with business intelligence, Yet Analytics helps organizations identify trends in employee behavior and performance. This data-driven approach allows businesses to enhance operational outcomes, measure experience data, and ultimately improve human capital performance.

Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology aimed at enhancing surgical outcomes. The company has developed a proprietary ultrasound-based platform that enables clinicians to detect anastomotic blood clots and assess critical intravascular flow metrics directly at the point of care. This technology not only facilitates the measurement of blood flow and vessel morphology but also includes bioresorbable and echogenic equipment to mark at-risk blood vessels for future assessments. By providing actionable data, Sonavex supports healthcare providers in monitoring and improving patient care, particularly in the context of post-operative complications.